Cholinesterase inhibitors do not alter the length of stay in nursing homes among patients with Alzheimer’s disease: a prospective, observational study of factors affecting survival time from admission to death

Table 2 Factors that Affected the AD patients’ Survival Time in Nursing Homes, years (Final General Linear Model)

Significant predictors^a	β	95 % CI	P value
Intercept	2.069	0.521, 3.618	0.009
Sex by living status^b
Females living with family	2.489	1.427, 3.551	<0.001
Females living alone	2.185	1.239, 3.130	<0.001
Males living alone	1.590	0.208, 2.972	0.024
Antihypertensive/cardiac therapy (no = 0, yes = 1)	−0.884	−1.599, −0.170	0.016
Anxiolytics/sedatives/hypnotics (no = 0, yes = 1)	−1.030	−1.908, −0.153	0.022
PSMS score at NHP	−0.119	−0.208, −0.030	0.009

β values were unstandardized and are expressed per 1 unit increase for continuous variables, and for the condition present for dichotomous variables
Apolipoprotein E genotype, duration of AD, age at NHP, years of education, cognitive or instrumental ADL abilities at NHP, cholinesterase inhibitor agent, dose or duration of treatment, other concomitant medications (antidiabetics, asthma medication, thyroid therapy, lipid-lowering agents, estrogens, nonsteroidal anti-inflammatory drugs/acetylsalicylic acid, antidepressants, or antipsychotics), the amount of home-help services, or adult day care at NHP or the annual mean changes in these services before NHP were not significant. There were no associations observed between survival time in nursing homes and the level of cognitive or functional response to cholinesterase inhibitors after 6 months of treatment, or rate of disease progression before NHP
AD Alzheimer’s disease, CI confidence interval, NHP nursing home placement, PSMS Physical Self-Maintenance Scale
^aDegree of explained variance, R = 0.458, R² = 0.210, P < 0.001
^bMales living with family were the reference category

ISSN: 1471-2377